Controversies in the Treatment of Mesothelioma of the Pleura

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable, stage III NSCLC.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

T-DXd rechallenge occurred after grade 1 ILD, and was proven safe for patients with breast cancer/solid tumors.

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.